OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totaling 272,194 shares, a growth of 31.9% from the March 31st total of 206,345 shares. Based on an average trading volume of 110,624 shares, the short-interest ratio is currently 2.5 days. Approximately 1.1% of the shares of the stock are short sold.

OKYO Pharma Trading Up 4.4%

OKYO stock traded up $0.07 during trading on Friday, hitting $1.63. The stock had a trading volume of 20,031 shares, compared to its average volume of 219,646. OKYO Pharma has a twelve month low of $1.31 and a twelve month high of $3.35. The company’s 50-day moving average price is $1.63 and its two-hundred day moving average price is $1.99.

OKYO Pharma (NASDAQ:OKYO) last issued its earnings results on Friday, January 30th. The company reported ($2.28) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($2.21). On average, sell-side analysts anticipate that OKYO Pharma will post -0.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Piper Sandler assumed coverage on OKYO Pharma in a research report on Friday, February 20th. They set an “overweight” rating and a $7.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of OKYO Pharma in a report on Tuesday, April 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of OKYO Pharma in a report on Thursday, January 29th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $6.33.

Institutional Trading of OKYO Pharma

Institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new stake in OKYO Pharma in the third quarter valued at approximately $31,000. XTX Topco Ltd purchased a new stake in shares of OKYO Pharma during the fourth quarter worth $36,000. Finally, Renaissance Technologies LLC grew its stake in shares of OKYO Pharma by 235.0% during the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after purchasing an additional 96,800 shares in the last quarter. Hedge funds and other institutional investors own 2.97% of the company’s stock.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.